HIV

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

Both trial sub-analyses will be presented at the virtual 23rd International AIDS Conference.

Survey results on PrEP access and utilization during COVID-19 shelter-in-place orders presented at the 23rd International AIDS Conference.

Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.

Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.

Virtual care takes center stage amid the pandemic.

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV. 

In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.

Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.

At the 2020 Conference on Retroviruses and Opportunistic Infections (CROI), longer-term study results on emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for HIV PrEP were presented.

Quicker referral time to youth-friendly care services could help younger patients with HIV achieve better outcomes.

The study evaluated whether antiretroviral therapy prescribing practices reflected current national guidelines.

The New Drug Application is seeking approval for ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine for the treatment of HIV in adults.

Walgreens, CVS Health, and Rite Aid are supporting the recently-launched “Ready, Set, PrEP” program.

What new laws could mean for pharmacies’ role in combatting HIV.

A new law gives pharmacists increased authority.